Health

STAT+: Most cancer drugs approved by European regulators lack a high clinical benefit, analysis finds

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 23/10/2026, 18:51:24 UTC.

Briefings

A new analysis indicates that most cancer drugs approved by European regulators over a four-year period lack high clinical benefit, with only 31% of 97 approved indications offering such benefit. Just nine medications received top-grade approval from the European Society for Medical Oncology, and five Asian-based drugmakers controlled over half of the 30 high-benefit indications approved between January 2022 and July 2026.

Key points

• Only 31% of 97 approved cancer indications offered a high clinical benefit during the analyzed period.
• Five drugmakers based in China or Japan accounted for more than half of all 30 high-benefit indications approved between January 2022 and July 2026.

Context

The analysis examines European regulatory approvals of cancer treatments over a four-year window, highlighting a shift where Asian pharmaceutical companies dominate high-benefit approvals.

Limitations

Data covers only four years (2022-2026) and relies on a single analysis source; specific clinical outcomes beyond benefit measurement are not detailed.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 23/10/2026, 18:52:28 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeic63oaofhey5664ob32ivxalrd2jhkgqg6pmlqz2azpn6zozfui64